Literature DB >> 24571073

Is gonorrhea becoming untreatable?

Paula Bianca Blomquist1, Victoria F Miari, Jane P Biddulph, Bambos M Charalambous.   

Abstract

An estimated 498 million new cases of curable sexually transmitted infections occur worldwide annually. Of these, 106 million are gonococcal infections, rendering gonorrhea the second most prevalent bacterial sexually transmitted infection after chlamydia. A decline in susceptibility to extended-spectrum cephalosporins, as well as treatment failures, have been identified worldwide. This, together with the associated epidemiological and socioeconomic burden, is of increasing concern. Currently, the effectiveness of antibiotic resistance control measures is limited. Barriers include the lack of therapeutic options, the difficulties of reducing high-risk sexual behavior and Neisseria gonorrhoeae's propensity to rapidly acquire resistance determinants. While the disease remains treatable for the moment, we need to anticipate and be prepared for the arrival and spread of untreatable gonorrhea by using a multifaceted approach and search for other, perhaps novel control strategies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24571073     DOI: 10.2217/fmb.13.155

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  9 in total

1.  Repurposing salicylamide for combating multidrug-resistant Neisseria gonorrhoeae.

Authors:  Marwa Alhashimi; Abdelrahman Mayhoub; Mohamed N Seleem
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

2.  Pharyngeal Gonorrhoea: The Willingness of Australian Men Who Have Sex with Men to Change Current Sexual Practices to Reduce Their Risk of Transmission-A Qualitative Study.

Authors:  Sandra Walker; Clare Bellhouse; Christopher K Fairley; Jade E Bilardi; Eric P F Chow
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

3.  A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the OMEGA (Oral Mouthwash use to Eradicate GonorrhoeA) study protocol.

Authors:  Eric P F Chow; Sandra Walker; Jane S Hocking; Catriona S Bradshaw; Marcus Y Chen; Sepehr N Tabrizi; Benjamin P Howden; Matthew G Law; Kate Maddaford; Tim R H Read; David A Lewis; David M Whiley; Lei Zhang; Andrew E Grulich; John M Kaldor; Vincent J Cornelisse; Samuel Phillips; Basil Donovan; Anna M McNulty; David J Templeton; Norman Roth; Richard Moore; Christopher K Fairley
Journal:  BMC Infect Dis       Date:  2017-06-28       Impact factor: 3.090

4.  In Vitro Susceptibility to Closthioamide among Clinical and Reference Strains of Neisseria gonorrhoeae.

Authors:  Victoria F Miari; Priya Solanki; Yonek Hleba; Richard A Stabler; John T Heap
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

5.  Gonococcal resistance can be viewed productively as part of a syndemic of antimicrobial resistance: an ecological analysis of 30 European countries.

Authors:  Chris Kenyon; Sheeba S Manoharan-Basil; Christophe Van Dijck
Journal:  Antimicrob Resist Infect Control       Date:  2020-06-30       Impact factor: 4.887

6.  N-(1,3,4-Oxadiazol-2-yl)Benzamides as Antibacterial Agents against Neisseria gonorrhoeae.

Authors:  George A Naclerio; Nader S Abutaleb; Marwa Alhashimi; Mohamed N Seleem; Herman O Sintim
Journal:  Int J Mol Sci       Date:  2021-02-28       Impact factor: 5.923

7.  Rapid Detection of Neisseria gonorrhoeae Genomic DNA Using Gold Nanoprobes Which Target the Gonococcal DNA Uptake Sequence.

Authors:  Ella Carter; Sean A Davis; Darryl J Hill
Journal:  Front Cell Infect Microbiol       Date:  2022-07-08       Impact factor: 6.073

8.  Current levels of gonorrhoea screening in MSM in Belgium may have little effect on prevalence: a modelling study.

Authors:  J Buyze; W Vanden Berghe; N Hens; C Kenyon
Journal:  Epidemiol Infect       Date:  2018-02-01       Impact factor: 4.434

9.  Investments in sexually transmitted infection research, 1997-2013: a systematic analysis of funding awarded to UK institutions.

Authors:  Michael G Head; Joseph R Fitchett; Jackie A Cassell; Rifat Atun
Journal:  J Glob Health       Date:  2015-12       Impact factor: 4.413

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.